In this photo taken Thursday, Aug. 18, 2016, a giraffe walks across the savannah in Amboseli national park, Kenya, as the highest mountain in Africa Mount Kilimanjaro in Tanzania is seen in the background.
11
Dec
11
Dec
The BioCryst Pharmaceuticals Inc. to Post FY2016 Earnings of ($0.90) Per Share, Jefferies Group …
The biotechnology company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.08.
11
Dec
The Heron Therapeutics Inc. (HRTX) Releases Quarterly Earnings Results, Misses Estimates By …
Heron Therapeutics Inc. (NASDAQ:HRTX) issued its quarterly earnings data on Tuesday. The biotechnology company reported ($1.24) EPS for the …
11
Dec
The Ziopharm Oncology Inc. (ZIOP) Posts Quarterly Earnings Results, Hits Expectations
Ziopharm Oncology Inc. (NASDAQ:ZIOP) issued its earnings results on Wednesday. The biotechnology company reported ($0.11) earnings per share …
11
Dec
The Ligand Pharmaceuticals Inc. (LGND) Upgrade to Hold by The Zacks Investment Research
Ligand’s Captisol formulation technology has resulted in partnerships with … The biotechnology company reported $0.62 earnings per share for the …
11
Dec
Charlottesville biotech firms rising to meet Zika challenges
Several biotechnology companies in the Charlottesville area are working to combat the Zika virus. The CvilleBioHub, a new biotech networking …
10
Dec
Penkava: The attack of Martian Red Colony Fever
I don’t know if you’ve noticed it, but we earthlings are preparing to invade another planet. Yep, outright interplanetary imperialistic colonialism.
10
Dec
The BioCryst Pharmaceuticals Inc. (BCRX) Given Buy Rating at the HC Wainwright
BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Monday, November 7th. The biotechnology company reported …
10
Dec
The BioCryst Pharmaceuticals Inc. (BCRX) Given Buy Rating at the FBR & Co
The brokerage currently has a $6.00 price target on the biotechnology company’s stock. BCRX has been the subject of a number of other reports.
10
Dec
The Conatus Pharmaceuticals’ (CNAT) âBuyâ Rating Reiterate at the JMP Securities
The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.03.